Basilea Pharmaceutica Ltd

Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company headquartered in Allschwil, Switzerland, founded in 2000 as a spin-off from F. Hoffmann-La Roche. With approximately 150 employees, it focuses on discovering, developing, and commercializing innovative anti-infective drugs to address severe bacterial and fungal infections, tackling global health challenges like antimicrobial resistance and invasive fungal diseases. The company has successfully launched two key hospital products: Cresemba (isavuconazole), an antifungal agent approved in over 70 countries for invasive aspergillosis and mucormycosis, and Zevtera (ceftobiprole), a broad-spectrum antibiotic effective against multidrug-resistant bacteria like MRSA, approved in numerous regions including recent US FDA nods for bacteremia, skin infections, and pneumonia. Basilea maintains a robust pipeline, including clinical-stage candidates like Fosmanogepix and BAL2062 for novel antifungal therapies, and partners with global firms such as Astellas, Pfizer, and Innoviva for distribution across over 100 countries. Committed to ESG priorities like product safety, access to medicine, and human capital, it plays a vital role in advancing treatments for life-threatening infections in hospitals worldwide.